Individual dose–response profiles of MEK inhibitors, trametinib (MEK1/2), GDC-0623 (MEK1), and FAK inhibitor VS4718 were obtained across the human glioma panel. This evidence concerns the gene MAP2K7 and central nervous system cancer.